Food and Drug Administration in 2013 has the potential to reduce the radiation exposure of patients undergoing intra-arterial therapy (IAT) for liver cancer.
READ FULL ARTICLE
From Medical News Today
New device may reduce radiation exposure to patients with liver cancer
the Oncology Nurse Advisor take:
AlluraClarity, an FDA-approved X-ray guidance device, has the potential to reduce radiation exposure in patients with liver cancer undergoing intra-arterial therapy (IAT), according to a report to be presented at the Radiological Society of North America annual meeting in Chicago.
In a clinical trial, Jean-Francois Geschwind, MD, and fellow researchers at Johns Hopkins University School of Medicine and Kimmel Cancer Center used the device on 50 patients, the researchers found that it was able to reduce exposure by up to 80 percent compared to standard X-ray platforms for IAT. In addition, AlluraClarity produced images that were just as clear as the standard system.
Dr. Geschwind believes that the novel platform will be especially useful in patients who require repeat therapy and are especially vulnerable to radiation such as children, as well as physicians who are regularly exposed to radiation procedures.
AlluraClarity uses a series of real-time image processing algorithms in order to achieve high quality images that require lower radiation power. It is developed by Philips Healthcare.
